

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/699,563
Date Submitted: April 20, 2004				Filing Date	11/03/2003 APR 2 U 2004
(use as many sheets as necessary)				First Named Inventor	Bradford Van Wagenen
				Group Art Unit	Not yet assigned 1625
				Examiner Name	Not yet assigned
Sheet	2	of	2	Attorney Docket Number	085747-0299

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.				T*
Mond X		C. MONTOLIU et al., "Activation of the Metabotropic Glutamate Receptor mGluR5 Prevents Glutamate Toxicity in Primary Cultures of Cerebellar Neurons", The Journal of Pharmacology and Experimental Therapeutics, May 2, 1997; pp. 643-647; Vol. 281; The American Society of Pharmacology and Experimental Therapeutics; USA.				
X		Ksasovitskij et al., Chemical Abstracts, Vol. 123, No. 22, Abstract 299726w, 608h, page 477, 11/27/1995.				
X		Yurugi et al., Chemical Pharmaceutical Bulletin, Vol. 21, No. 8, pp., 1641-1650, 1973.				
X		William W. PAUDLER et al., "The Conversion of Imidazo[1,5-a]pyridines into 3-(2-Pyridyl)-1,2,4-oxadiazoles", Conversion of Imadazopyridines Into Pyridyloxadiazoles", August 1967, pp. 2430-2433; Vol. 32; USA.				
X		T. Ross KELLY et al., "Total Synthesis of Dimethyl Sulfoxymycinamate", Tetrahedron Letters, 1995; pp. 5319-5322, Vol. 36, No. 30, Elsevier Science Ltd. UK.				
X		Wei HUANG et al., "A Novel Improved Procedure for the Synthesis of Oxazoles", Tetrahedron; 1996; pp. 10131-10136, Vol. 52, No. 30; Elsevier Science Ltd., UK.				
X		Mark A. MASSA et al., "Synthesis of Novel Substituted Pyridines as Inhibitors of Endothelin Converting Enzyme-1 (ECE-1)", Bioorganic & Medicinal Chemistry Letters; 1998; pp. 2117-2122, Vol. 8, Elsevier Science Ltd., UK.				
X		Luciano VIO et al., "Note-low antihypertensive activity", Journal; 5807502; EN; 321; 1988; pgs. 713-717; Bellstein Institut zur Foerderung der Chimischen Wissenschaften; Weinheim Germany.				
X		Helene PERRIER, et al., "Substituted Furans as Inhibitors of the PDE4 Enzyme"; Bioorganic & Medicinal Chemistry Letters; 1999; pp. 323-328, Vol. 9, Elsevier Science Ltd. UK.				
		Edward E. GLOVER et al. "The Nitration of Imidazo[1,5-a] pyridines" J of the Chem. Soc., Perkins I, 1980, pp. 959-961.				
Yond		Robert K. HOWE et al., "Nitrile Oxide Cycloaddition Routes to 2-(Isoxazolyl)-benzoates and 2-(1,2,4-Oxadiazol-3-yl)benzoates", J. of Het. Chem., Vol. 19, 1982, pp. 721-728.				

X Did not receive

Examiner Signature	Zinne N Davis	Date Considered	4/8/2005
--------------------	---------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/699,563
Date Submitted: April 20, 2004				Filing Date	11/03/2003
(use as many sheets as necessary)				First Named Inventor	Bradford Van Wagenen APR 20 2004
				Group Art Unit	Not yet assigned 16252
				Examiner Name	Not yet assigned 2NDAYAS TRADEMARK OFFICE
Sheet	1	of	2	Attorney Docket Number	085747-0299

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
mond		3,647,809	A	Harsanyi et al.	3/7/1972	
		4,022,901	A	Narayanan et al.	5/10/1977	
		5,554,630		Teuber et al.	09/1990	
		3,647,809		Relter et al.	03/1972	
		5,554,630		Teuber et al.	9/10/1996	
mond		4,003,909		Narayanan et al.	1/18/1977	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ (if known)		
mond		WO 01 12627 A		NPS Pharmaceuticals Inc.	2/22/2001	
		WO 98 17652 A		Boehringer Ingelheim	4/30/1998	
		WO 99 02497 A		Novartis Erfindungen	1/21/1999	
		WO 97/0396706096		Rhone-Poulenc Rorer Limit	2/1997	
		WO 94/22846		Pfizer Inc.	10/1994	
		WO 94/22846	A1	Pfizer Inc.	10/13/1994	
		WO 97/03967	A1	RhonePoulenc Rorer Limited GB	02/06/1997	
		WO 99/26927	A2	NPS Pharmaceuticals, Inc.	06/03/1999	
		WO 98/57969		Hoechst Schering	12/1998	
mond		DE 1 149 011		Farbwerke Hoechst Aktiengesellschaft	5/22/1963	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.			
mond		M. OHKUBO et al., "Studies on Cerebral Protective Agents; VII. Synthesis of Novel 4-Acylazoles Derivatives with Anti-anoxic Activity", Chem. Pharmaceutical Bulletin; June 1995; pp. 947-954; Vol. 43; No. 6; Pharmaceutical Society of Japan.			
mond		W. PEI et al., "Convenient Synthesis of 2-Alkyl (Aryl)-4, 5-diphenyloxazoles and 2-Alkyl (Aryl)-4 phenyloxazoles", Synthesis; September 1998, pp. 1298-1304; No. 9, China.			

* Did not receive

Examiner Signature	Zinedine Davis	Date Considered	4/8/2005
--------------------	----------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, PO Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.